PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Price Stock Quantity  
USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PD184352 (CI-1040) Chemical Structure

PD184352 (CI-1040) Chemical Structure
Molecular Weight: 478.67

Validation & Quality Control

Cited by 43 publications:

12 customer reviews :

Quality Control & MSDS

Related Compound Libraries

PD184352 (CI-1040) is available in the following compound libraries:

MEK Inhibitors with Unique Features

Product Information

  • Compare MEK Inhibitors
    Compare MEK Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Targets MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
IC50 17 nM 17 nM
In vitro CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
H9MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;v[GlEPTB;MD6wNlI4PiEQvF2=MmTLV2FPT0WU
CHP-212MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnrcmpzUUN3ME2wMlAzQDh3IN88US=>NFLaeItUSU6JRWK=
EoL-1-cellM1HxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHJXHM2UUN3ME2wMlA1OTV{IN88US=>NEntbItUSU6JRWK=
DU-4475MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU[2WGtbUUN3ME2wMlA4PTl7IN88US=>MXXTRW5ITVJ?
MMAC-SFMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTBwMUC5O|Qh|ryPMVjTRW5ITVJ?
AGSNGrKUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTBwMUG3NVMh|ryPM{HpPHNCVkeHUh?=
M14NEfoO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfnZ21sUUN3ME2wMlE2PDZ6IN88US=>Mk[1V2FPT0WU
CP50-MEL-BMmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFuxc2tKSzVyPUCuNVczPTRizszNNFuwW4ZUSU6JRWK=
C32NFLzUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWj4PZI2UUN3ME2wMlE6ODd{IN88US=>NXrHc20zW0GQR1XS
KMOE-2MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\BXGdKSzVyPUCuNVk4QTVizszNNX3UZ5AxW0GQR1XS
A101DNHrYRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{G0W2lEPTB;MD6yNVQh|ryPMULTRW5ITVJ?
KM12MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXlOYFIUUN3ME2wMlI1ODV5IN88US=>MUfTRW5ITVJ?
HSC-4NIWzWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjJTWM2OD1yLkK0N|k2KM7:TR?=NHvTUVhUSU6JRWK=
NOMO-1NHHtTnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4e1[WlEPTB;MD6yOVc1OiEQvF2=MWDTRW5ITVJ?
MZ7-melNWHz[oVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPFRoNKSzVyPUCuNlY{PCEQvF2=MkPjV2FPT0WU
ACNMnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fafmlEPTB;MD6yOlc{PyEQvF2=MnvJV2FPT0WU
MEL-HONXXicmVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2q2ZmlEPTB;MD6yO|Y2OiEQvF2=MkjmV2FPT0WU
BHT-101M4DrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7Ub3pKSzVyPUCuNlg3ODZizszNMWLTRW5ITVJ?
SK-MEL-28NGj3b3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfKTWM2OD1yLkOwOFA6KM7:TR?=NEOyOZZUSU6JRWK=
KG-1MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLFTWM2OD1yLkOwOlY5KM7:TR?=MW\TRW5ITVJ?
COLO-679Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTBwM{K3NkDPxE1?MV;TRW5ITVJ?
SK-MEL-24M2DiOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHm3OnZKSzVyPUCuN|I5OTNizszNNIf0OWZUSU6JRWK=
G-361MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;VWGxjUUN3ME2wMlM3Pzl3IN88US=>NEfJe3ZUSU6JRWK=
KY821M1\qdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTBwM{e5NUDPxE1?MkfxV2FPT0WU
KASUMI-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTBwM{m5JO69VQ>?MnjTV2FPT0WU
HL-60NWXSdm1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDRcYczUUN3ME2wMlQyOTB5IN88US=>M3jONXNCVkeHUh?=
K5NUO2VZdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTBwNEOxNVch|ryPM1vUUHNCVkeHUh?=
KU812NVHmT|VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYT5RmtmUUN3ME2wMlQ2Ojl7IN88US=>M17LWHNCVkeHUh?=
SH-4Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHOU45oUUN3ME2wMlQ3OjV4IN88US=>MkfYV2FPT0WU
HTC-C3NXjvc5dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2q3V2lEPTB;MD60OlU{OSEQvF2=NILISppUSU6JRWK=
CP66-MELNE\3doVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTBwNEi4NFkh|ryPMYPTRW5ITVJ?
WM-115M3Xybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULzb4gzUUN3ME2wMlQ6OjV5IN88US=>MYjTRW5ITVJ?
A2780NVHudoJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTBwNEm4NlMh|ryPM{fUSHNCVkeHUh?=
P12-ICHIKAWANIfsNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzz[o9yUUN3ME2wMlYyOjJzIN88US=>NEfm[oRUSU6JRWK=
HMV-IINXrVb3J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rOe2lEPTB;MD62OFQ3PSEQvF2=MYLTRW5ITVJ?
HT-144MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTBwNkS2OVch|ryPNGHZXYlUSU6JRWK=
LB2518-MELM13C[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTBwN{G2N|Ih|ryPNHPmdJBUSU6JRWK=
NCI-SNU-1NIX4cHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXuTWM2OD1yLke1OFM{KM7:TR?=MkPkV2FPT0WU
C2BBe1NEXGNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDDR5FKSzVyPUCuPFExOjNizszNMX3TRW5ITVJ?
PSN1MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TOSmlEPTB;MD65OlE6PiEQvF2=NGTjT2pUSU6JRWK=
UACC-257MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nsSWlEPTB;MD65OlQ4OyEQvF2=NX3PVGo6W0GQR1XS
RVH-421NV\mbJJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGribI5KSzVyPUCuPVcyQCEQvF2=M{LLVHNCVkeHUh?=
GP5dNEXCXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITrZ2xKSzVyPUCuPVg{ODhizszNM37MOHNCVkeHUh?=
TYK-nuMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFS3dlNKSzVyPUGuNFMyPzJizszNMn;iV2FPT0WU
SK-N-ASNFvYR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LhRmlEPTB;MT6wO|k1PyEQvF2=NFHVfWVUSU6JRWK=
SW620MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYX5WYRxUUN3ME2xMlE{PTN2IN88US=>NH;6bIJUSU6JRWK=
HuP-T4MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LHPWlEPTB;MT6xPFM2QSEQvF2=NXfIbmVNW0GQR1XS
A549Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVH6N|JuUUN3ME2xMlE6PTd4IN88US=>MnezV2FPT0WU
MewoMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4r6SmlEPTB;MT6yNFI4PiEQvF2=MlL4V2FPT0WU
ONS-76M3PSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX:5W5dnUUN3ME2xMlIzODR7IN88US=>M1LJRnNCVkeHUh?=
SK-MEL-1NGS4[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljqTWM2OD1zLkKzOFE6KM7:TR?=MVzTRW5ITVJ?
RCM-1NG\nXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTFwMkSwOFch|ryPM13KPHNCVkeHUh?=
H-EMC-SSMo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTFwMkm2NFgh|ryPM3fONXNCVkeHUh?=
NCI-H2291Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTFwM{K1N|Yh|ryPNGHGS5VUSU6JRWK=
SW1463MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\aTWM2OD1zLkOzO|IyKM7:TR?=MXnTRW5ITVJ?
LS-411NNVTDSWVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTFwNEC1NVch|ryPM1O1ZnNCVkeHUh?=
BV-173NWLtSIhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjVRXhjUUN3ME2xMlQ1ODF3IN88US=>MVPTRW5ITVJ?
LS-513NEjRc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4O0UmlEPTB;MT60OVE6OiEQvF2=NFrMV41USU6JRWK=
LoVoNHroc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1K0cmlEPTB;MT60OlM6QSEQvF2=MkjWV2FPT0WU
HO-1-N-1NUHDSm5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTQWZAxUUN3ME2xMlUyPjN2IN88US=>NWjRTplvW0GQR1XS
ML-2M3fvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTMeWw5UUN3ME2xMlUzQDZ6IN88US=>M2DG[XNCVkeHUh?=
NCI-H1437MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXToW41HUUN3ME2xMlU2Ojd3IN88US=>M2X0W3NCVkeHUh?=
SW1116NYLrN3ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HJVmlEPTB;MT61OlM6QCEQvF2=MkO4V2FPT0WU
A4-FukM4HnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTFwNUewOFUh|ryPNFvNeIdUSU6JRWK=
HD-MY-ZMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrQbmRKSzVyPUGuOVc{PzZizszNM4T4Z3NCVkeHUh?=
SK-MEL-2NWXzb5FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPPc2dKSzVyPUGuOVc1PTlizszNMVjTRW5ITVJ?
RT-112NWnS[nVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUflZpY6UUN3ME2xMlU5QTV{IN88US=>MkDJV2FPT0WU
COLO-829Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnOTWM2OD1zLk[yNlMzKM7:TR?=MkfhV2FPT0WU
OVCAR-5M3GxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnLVWk{UUN3ME2xMlc4Pjh5IN88US=>NG\Wd|dUSU6JRWK=
NB69NFz0UIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfmT41TUUN3ME2xMlc5PDZ7IN88US=>MV7TRW5ITVJ?
NCI-H292NXrhcHhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rEXGlEPTB;MT64OlY6QSEQvF2=NV32VpRmW0GQR1XS
LOXIMVIM1K2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3ZOmliUUN3ME2xMlg6PDJ5IN88US=>NVXyV3FKW0GQR1XS
BPH-1NE\QbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGD5bVRKSzVyPUGuPFk2QTFizszNNEjzfpVUSU6JRWK=
A375NEjhcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmWwTWM2OD1zLki5O|E1KM7:TR?=NIfyU3FUSU6JRWK=
LCLC-97TM1NYfERW42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmT0TWM2OD1zLkmyNlU3KM7:TR?=Mm\VV2FPT0WU
RXF393NGHOXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;0W|FjUUN3ME2xMlk4QDh5IN88US=>M{fYc3NCVkeHUh?=
HCC70MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHn3c2JKSzVyPUKuNFI1OjZizszNMkToV2FPT0WU
EM-2MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7F[3RDUUN3ME2yMlA4OTl6IN88US=>NVvh[lZGW0GQR1XS
MZ2-MELM1z5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTJwMUGxNlch|ryPNXXzTVF2W0GQR1XS
HNMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnu5TWM2OD1{LkG2Nlc5KM7:TR?=NUj0eHpKW0GQR1XS
A2058MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{T4V2lEPTB;Mj6xPVI4QSEQvF2=M3XhNHNCVkeHUh?=
NB7M2\2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHtZ3hZUUN3ME2yMlM1ODh4IN88US=>NVPG[m1wW0GQR1XS
DOKMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHZbVBHUUN3ME2yMlM2Pzd|IN88US=>NHfPUlJUSU6JRWK=
CAL-27NYq2UVRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TOSGlEPTB;Mj6zPVI{PiEQvF2=NGHCcFVUSU6JRWK=
BB65-RCCM1LzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\3R2RKSzVyPUKuOFA3PzRizszNNHnNWnJUSU6JRWK=
RDMmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTJwNES3NlMh|ryPNWnHXHZnW0GQR1XS
KNS-62MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TDO2lEPTB;Mj61NVE3PCEQvF2=NH64ZXJUSU6JRWK=
EW-13NGPF[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTJwNU[zN|kh|ryPMULTRW5ITVJ?
DBMn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGP0[oxKSzVyPUKuOVg4QDhizszNNYPzRXRxW0GQR1XS
HCC2218NXLE[XZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDOOJRKSzVyPUKuOlQ4PzhizszNNYjG[oF6W0GQR1XS
L-363MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTJwN{SzO{DPxE1?MnPkV2FPT0WU
CHL-1NVPvWnBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTJwOEC3PFUh|ryPM4rQ[3NCVkeHUh?=
BFTC-905M4S2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF65WGpKSzVyPUKuPFI2OyEQvF2=NWDFcGJxW0GQR1XS
HCE-TMkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml6zTWM2OD1{LkizNlY1KM7:TR?=NFn5WXBUSU6JRWK=
COLO-792M3HxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPlelJJUUN3ME2yMlg1ODJ5IN88US=>M1ryb3NCVkeHUh?=
LB2241-RCCMl3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTJwOEW4PVMh|ryPM{i4eXNCVkeHUh?=
CAL-39NV3zdGNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXGTWM2OD1{Lki5PVk6KM7:TR?=Mom3V2FPT0WU
T-24NYLpe3ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTJwOUGxNVIh|ryPNE\zWHlUSU6JRWK=
NCI-H727M4nSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTJwOUG3PVYh|ryPNXPPWJd{W0GQR1XS
Ca9-22NXL3bGZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3SVlFKSzVyPUKuPVczPTVizszNMmfWV2FPT0WU
MIA-PaCa-2NVLVXGYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTZTWM2OD1|LkCwO|gyKM7:TR?=MV\TRW5ITVJ?
HT-1080MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nLVGlEPTB;Mz6wNVk6PyEQvF2=M2TBPHNCVkeHUh?=
D-423MGMnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDWTWM2OD1|LkC3O|U{KM7:TR?=NXfJZYZkW0GQR1XS
LAMA-84NHGxc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{GxVGlEPTB;Mz6xN|U5KM7:TR?=MojFV2FPT0WU
SW780MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnflTWM2OD1|LkG0NlI6KM7:TR?=NWHKR49LW0GQR1XS
KU-19-19NV;5b4N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\QTWM2OD1|LkG3NFM1KM7:TR?=Mm[yV2FPT0WU
COLO-741NWP1NnZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3WOIxKSzVyPUOuNVg3PzNizszNNHXa[GRUSU6JRWK=
HSC-3NUHLboVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjmNGlKSzVyPUOuNlMyPTFizszNMVfTRW5ITVJ?
SN12CM1TXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTNwMkS3NFEh|ryPNXnZNFRUW0GQR1XS
786-0M3LpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4qxSmlEPTB;Mz6yO|I1OyEQvF2=NYLuendNW0GQR1XS
GAKM4jZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTNwM{K1OlEh|ryPMWDTRW5ITVJ?
PANC-03-27M2LaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTNwM{WwOFUh|ryPM3vte3NCVkeHUh?=
CTB-1Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nrXWlEPTB;Mz60O|A1PyEQvF2=MYPTRW5ITVJ?
A427NIi0NXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXW5RnA1UUN3ME2zMlU6PTV4IN88US=>MVLTRW5ITVJ?
EGI-1M3\3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXk[21KSzVyPUOuOlA2QDNizszNM1rGcHNCVkeHUh?=
U-2-OSNI\veZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfQUZVKSzVyPUOuOlczPTZizszNNWjLSmQ2W0GQR1XS
NCI-SNU-5Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvWOGhKSzVyPUOuOlc4OyEQvF2=M2[5ZXNCVkeHUh?=
SK-LU-1NIDSSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXTpc4JLUUN3ME2zMlY5Pzl6IN88US=>MYDTRW5ITVJ?
697MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDBfXhKSzVyPUOuOlk3ODNizszNM4PueXNCVkeHUh?=
HPAF-IIM{TCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTNwN{W0PUDPxE1?M2CzWXNCVkeHUh?=
NCI-H2087M1TnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTNwOES2O|Ih|ryPNWG0PWJ2W0GQR1XS
SK-MEL-3NWHUS|lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTNwOEWxOVQh|ryPNIT5SZpUSU6JRWK=
CGTH-W-1M1j3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nYc2lEPTB;Mz64OVczPSEQvF2=MX\TRW5ITVJ?
8505CMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX2yNINHUUN3ME2zMlkxODd6IN88US=>M4PEVXNCVkeHUh?=
GAMGNEDJNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\nb2lEPTB;ND6wNlM4PyEQvF2=MVTTRW5ITVJ?
SW626NVmzXG91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\YTWM2OD12LkC0OFgh|ryPNFLMcmpUSU6JRWK=
CAL-62MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjMZ2ZKSzVyPUSuNFc1OyEQvF2=M4XSWHNCVkeHUh?=
MHH-PREB-1NGKxdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlT1TWM2OD12LkGyNVEyKM7:TR?=MmW0V2FPT0WU
RPMI-7951NYD5[WdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXBXooyUUN3ME20MlI2PTh7IN88US=>Ml\KV2FPT0WU
HOP-92MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\pTWM2OD12LkK1Olch|ryPNHy5fI9USU6JRWK=
MDA-MB-231MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTRwMkmyNlMh|ryPNV3FcpNjW0GQR1XS
LAN-6MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2O1XmlEPTB;ND6zNVY{PyEQvF2=NH3oXo1USU6JRWK=
ALL-POM{TlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnTVHNKSzVyPUSuN|YyPTZizszNNIX3dmNUSU6JRWK=
HHMorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHz0UHdKSzVyPUSuOFE2QTdizszNMWDTRW5ITVJ?
IGROV-1M{TSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HGRmlEPTB;ND60OVE4OSEQvF2=M1GzOXNCVkeHUh?=
NCI-H358MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTRwNEWzPFUh|ryPNIG5TW5USU6JRWK=
NB5MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTRwNkCzOlkh|ryPMl3GV2FPT0WU
NCI-H747MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPsTWM2OD12Lk[4PFA4KM7:TR?=M3Tn[nNCVkeHUh?=
NH-12NFfvb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTRwN{G2NlUh|ryPNETLZZRUSU6JRWK=
LB1047-RCCNX7kO2hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIryZ2FKSzVyPUSuO|M5OTVizszNM1m3Z3NCVkeHUh?=
EFO-27Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnm3TWM2OD12Lke4OlY4KM7:TR?=M4\QTHNCVkeHUh?=
EPLC-272HNHK1WW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;tTWM2OD12Lkm5OlY6KM7:TR?=MVLTRW5ITVJ?
CAL-54M1TD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTVwMEK2PVUh|ryPMWHTRW5ITVJ?
H4NVG5WZdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXtTWM2OD13LkC0NlU2KM7:TR?=MWDTRW5ITVJ?
MOLT-13M2HMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;wTWM2OD13LkC2O|c3KM7:TR?=NGflU5hUSU6JRWK=
CAL-33M13SNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTVwMUKzNVch|ryPM4DpdXNCVkeHUh?=
23132-87MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mom1TWM2OD13LkG2PFczKM7:TR?=NYnmVHpYW0GQR1XS
UM-UC-3Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1i2SGlEPTB;NT6xPFA1PyEQvF2=NEXzbW5USU6JRWK=
HuH-7NVrtbI5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljsTWM2OD13LkK3NVQ4KM7:TR?=MVfTRW5ITVJ?
BCPAPM4\KR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTNTWM2OD13LkOyPVY6KM7:TR?=M3PRbHNCVkeHUh?=
AsPC-1NXL0NY9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfXNmZKSzVyPUWuN|Y4PjNizszNNXLNcmh{W0GQR1XS
NCI-H1155NWrnbol6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTVwNECwOVEh|ryPM3KxU3NCVkeHUh?=
GT3TKBM{\MXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTYTWM2OD13LkS2OVk5KM7:TR?=MkXQV2FPT0WU
HCC2998NETEXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LuRWlEPTB;NT60PVExQSEQvF2=NXzFWWpDW0GQR1XS
NUGC-3NYeyPYVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPyVlk2UUN3ME21MlQ6OzB{IN88US=>M4jmRXNCVkeHUh?=
Hs-578-TNHqwZ3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;kV2lEPTB;NT61N|c6PCEQvF2=MVPTRW5ITVJ?
FADUNEe2XHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rwNGlEPTB;NT61OVczPiEQvF2=M{W3WHNCVkeHUh?=
NBsusSRM{TmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTVwNUexOVUh|ryPMYfTRW5ITVJ?
ME-180MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTVwNUiwPVIh|ryPM{TudHNCVkeHUh?=
SW1710MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTVwNkG2OVQh|ryPMXTTRW5ITVJ?
HuP-T3MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHHTWM2OD13Lk[yNFI6KM7:TR?=MlvEV2FPT0WU
HOSMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTVwNkK5NlMh|ryPM33EfnNCVkeHUh?=
PA-1MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HWOGlEPTB;NT62OFI3PSEQvF2=NWDEXYdZW0GQR1XS
LU-99AMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\pUWlEPTB;NT62OlQ2OSEQvF2=Mk\XV2FPT0WU
RS4-11NFXGfoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXCRpQ2UUN3ME21MlY3Pzd3IN88US=>MUDTRW5ITVJ?
TE-8NYS0Z5o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;0TWM2OD13Lk[4OVM4KM7:TR?=M4HTS3NCVkeHUh?=
RERF-LC-MSMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTVwNki4NFMh|ryPNXj5T5lkW0GQR1XS
MEL-JUSOM4HTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HkSGlEPTB;NT63N|c5KM7:TR?=M1nXdnNCVkeHUh?=
SK-MES-1MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\ISWZDUUN3ME21Mlg{PTJ6IN88US=>M2qycHNCVkeHUh?=
D-263MGM3rrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTVwOEizOVEh|ryPNXL0U5RuW0GQR1XS
NB10NXX0TpQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXPTWM2OD13Lki5OFYh|ryPNX7DWng2W0GQR1XS
SK-HEP-1NX\HV5ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zqemlEPTB;NT65N|Q4OSEQvF2=M1XvTHNCVkeHUh?=
HT-29M3LpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVK3THA3UUN3ME21Mlk5OTF6IN88US=>MYXTRW5ITVJ?
KYSE-140NFnPUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWj1NpdiUUN3ME22MlAzOTh{IN88US=>Mm\YV2FPT0WU
NCI-H1666NFPjU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlW2TWM2OD14LkC4OFYyKM7:TR?=M2jZOXNCVkeHUh?=
NCI-H1304M2DHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmC1TWM2OD14LkG5PVQh|ryPMn:zV2FPT0WU
RPMI-8866Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjOPFVKSzVyPU[uNlE{OTNizszNMVfTRW5ITVJ?
MV-4-11MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXuTWM2OD14LkKzNVk6KM7:TR?=M2roSnNCVkeHUh?=
A431MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TjXWlEPTB;Nj6yOFI6PiEQvF2=MVfTRW5ITVJ?
PANC-10-05NEDqeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1n6UGlEPTB;Nj6yPFM3OyEQvF2=NXjvUVBUW0GQR1XS
TK10NFTZPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fqN2lEPTB;Nj6zNlYxPCEQvF2=MWLTRW5ITVJ?
NCI-H1975NX6xO2RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkH1TWM2OD14LkS3NlE2KM7:TR?=MX7TRW5ITVJ?
A172MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PPO2lEPTB;Nj60PVE4PiEQvF2=MWrTRW5ITVJ?
D-566MGNFnBblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITwb5FKSzVyPU[uOVQ{ODNizszNNYW0N4w4W0GQR1XS
NCI-H2122M12yZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTZwNkG1Nlgh|ryPNUDGXmh4W0GQR1XS
COR-L105M4\1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTZwNkWyO|Uh|ryPNHzzOIRUSU6JRWK=
AN3-CANX\KVWFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Cw[GlEPTB;Nj62PFY1OSEQvF2=M4PiNXNCVkeHUh?=
Calu-6NUXDTIlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTZwN{m2PVgh|ryPMlvGV2FPT0WU
HCT-116NIfRZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoiyTWM2OD14LkixNlY1KM7:TR?=M1XTSnNCVkeHUh?=
MHH-NB-11NVW4coR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjMbplKSzVyPU[uPFUxODJizszNNF\L[XBUSU6JRWK=
MFE-280NYD0O2prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTZwOEW5PFMh|ryPM1LVOHNCVkeHUh?=
SW1088M4S5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3kRVJKSzVyPU[uPVE6OTNizszNNUHqT3BqW0GQR1XS
SW48MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHtS|l{UUN3ME22Mlk1PTFizszNNGPKeXlUSU6JRWK=
HuCCT1M2H5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\hNGc{UUN3ME23MlAyODN5IN88US=>MYXTRW5ITVJ?
ACHNM1LHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHvN3BKSzVyPUeuNFI6PDNizszNMmOwV2FPT0WU
8305CMnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPSTWM2OD15LkC5PVk2KM7:TR?=M1:5W3NCVkeHUh?=
DoTc2-4510MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLWTWM2OD15LkGyNVUh|ryPNHXJboxUSU6JRWK=
COR-L23NX6zOYhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmm3TWM2OD15LkK0OFIh|ryPMmn5V2FPT0WU
SK-MEL-30M{HmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\Ne5JYUUN3ME23MlI2ODh|IN88US=>MnTFV2FPT0WU
BE-13M4foUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MomzTWM2OD15LkOzPFM1KM7:TR?=NWTRSI9kW0GQR1XS
GR-STMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnrTHdKSzVyPUeuOFAyPzRizszNNIXVUVZUSU6JRWK=
LU-135NULKfndvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTdwNUW5N|kh|ryPNX7ve3U{W0GQR1XS
U-266NYrYVIczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXFeGdmUUN3ME23MlU3Ojh4IN88US=>M2r3T3NCVkeHUh?=
NCI-H1355MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDpUIxKSzVyPUeuOVg3OzVizszNMnTpV2FPT0WU
NB14Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTdwNk[2OFIh|ryPMU\TRW5ITVJ?
SCC-25NWnBe|hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;lXGlEPTB;Nz63NFkh|ryPMnfLV2FPT0WU
COLO-678NWfDSFV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrZcJBKSzVyPUeuO|ExPzZizszNNHOzVZBUSU6JRWK=
TGBC1TKBNFTJfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXxTWM2OD15Lki5N|k5KM7:TR?=MoPNV2FPT0WU
IST-MEL1NVfxWm1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonQTWM2OD16LkCwOFA3KM7:TR?=MU\TRW5ITVJ?
ECC10M2mzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFi3OZFKSzVyPUiuNFM{QTVizszNMlraV2FPT0WU
EW-16M2K0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDQTWM2OD16LkC4OFQ2KM7:TR?=NVvGNpA1W0GQR1XS
DOHH-2MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXMR|BKSzVyPUiuNlAxQTVizszNMV\TRW5ITVJ?
NCI-H1581MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHTTWM2OD16LkK2N|I{KM7:TR?=NGPGT2NUSU6JRWK=
TE-5MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfNb4RGUUN3ME24MlQzPDJ7IN88US=>M1rUbnNCVkeHUh?=
CAKI-1NIjScWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRThwNUeyNlIh|ryPNH3yOWdUSU6JRWK=
A673MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRThwNkOyNFIh|ryPMYXTRW5ITVJ?
CAL-12TMnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRThwNkW3OVMh|ryPNGC4THpUSU6JRWK=
DBTRG-05MGNHzpUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHhZWd4UUN3ME24Mlc1QDV7IN88US=>MYjTRW5ITVJ?
SK-N-FINF;6[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYL2W3FyUUN3ME24MlgyOzd7IN88US=>Mn30V2FPT0WU
K-562NF;MT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVWzS4p[UUN3ME24Mlg{QTV5IN88US=>MkjCV2FPT0WU
SBC-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrVb|NKSzVyPUiuPFY3PDVizszNNXXaTYZRW0GQR1XS
ES4NHW1PHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvXdmFDUUN3ME24Mlg3QDh2IN88US=>NVvXcYJsW0GQR1XS
MS-1NYP0VGJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRThwOEe1NVch|ryPNI\BPYxUSU6JRWK=
RKONEe3PJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoH2TWM2OD16Lki5NFU4KM7:TR?=MWXTRW5ITVJ?
NCI-H1693MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HuSWlEPTB;OD65NlE4KM7:TR?=MWnTRW5ITVJ?
SW954MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NID1U2tKSzVyPUiuPVY6PzhizszNNGfFcI9USU6JRWK=
SK-UT-1M{P2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUX5XHlpUUN3ME24Mlk4Pjh|IN88US=>NWDZboRXW0GQR1XS
T98GNH3TZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRThwOUm4OFYh|ryPM{XUenNCVkeHUh?=
NCI-H2126NFjCeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjtfFJKSzVyPUmuNFA5OjZizszNMnLRV2FPT0WU
TE-12M1fzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn[0TWM2OD17LkCzN|Y4KM7:TR?=NXPsU25{W0GQR1XS
DK-MGM4\KSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHSTWM2OD17LkKxNVkyKM7:TR?=NV36SVJpW0GQR1XS
MEG-01NFjNe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljGTWM2OD17LkK0PVMyKM7:TR?=NXKwT2JTW0GQR1XS
HCC1937M1vVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1[0SGlEPTB;OT6yPVA6OSEQvF2=NXHLdJR3W0GQR1XS
MKN45Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTlwNEWwOlUh|ryPNFzpdZZUSU6JRWK=
NCI-H1792NV7VR2U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17GSGlEPTB;OT60OVIyQSEQvF2=MWXTRW5ITVJ?
SW1417MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTlwNU[4N|ch|ryPMmT5V2FPT0WU
639-VMnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fjfGlEPTB;OT62OFM5QCEQvF2=M4Pl[nNCVkeHUh?=
P30-OHKMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkO3TWM2OD17Lk[1N|E3KM7:TR?=MUnTRW5ITVJ?
YKG-1NXO0eFdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjqRYdoUUN3ME25Mlc2ODN|IN88US=>MU\TRW5ITVJ?
KGNNXn6XXV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fvbGlEPTB;OT64N|c6PSEQvF2=NVPFdIVCW0GQR1XS
MSTO-211HMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DxdGlEPTB;OT65OVUzQSEQvF2=MmO0V2FPT0WU
NCI-H1573NWfZWmhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGKz[lRKSzVyPUGwMlE2PzRizszNNFHsfnVUSU6JRWK=
NCI-H720MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknhTWM2OD1zMD6xPVg6KM7:TR?=MWnTRW5ITVJ?
KARPAS-45M{nLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTFyLkK3PVUh|ryPNXHNTHk{W0GQR1XS
MDA-MB-175-VIIMoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnS1TWM2OD1zMD60PEDPxE1?NF\jbIJUSU6JRWK=
SK-NEP-1M{nS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXKZ2xKSzVyPUGwMlQ6QDFizszNMYDTRW5ITVJ?
MKN28MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHjWG9KSzVyPUGwMlUyQCEQvF2=MmHDV2FPT0WU
KYSE-520M4PpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvRVHlKSzVyPUGwMlUzKM7:TR?=NFzzTYFUSU6JRWK=
KE-37NUfnO5dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M334NGlEPTB;MUCuOVI4OiEQvF2=NUDhOldHW0GQR1XS
VA-ES-BJMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorjTWM2OD1zMD61Olch|ryPM1nUe3NCVkeHUh?=
CCRF-CEMMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DrU2lEPTB;MUCuOVY5PCEQvF2=MlnuV2FPT0WU
GMS-10MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4KweWlEPTB;MUCuOlA6PCEQvF2=NUXBeFNwW0GQR1XS
NCI-H1623M33Fd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTFyLk[zO|kh|ryPMWLTRW5ITVJ?
NEC8M1fEU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTRTWM2OD1zMD63O|c{KM7:TR?=NXjLUZZ6W0GQR1XS
MOLT-16MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfKTWM2OD1zMD64NVE{KM7:TR?=MXHTRW5ITVJ?
DJM-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfId2ZKSzVyPUGxMlA{PzlizszNNHm2c3BUSU6JRWK=
U251M{fzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1ruO2lEPTB;MUGuNFQzKM7:TR?=NV;LToU5W0GQR1XS
SBC-5MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{H6WGlEPTB;MUGuNVQ3PyEQvF2=NIDkfW5USU6JRWK=
SW756NV6zW2hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVT1WJI2UUN3ME2xNU4zOTV2IN88US=>NFnOS3RUSU6JRWK=
KS-1NFzofFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnT5TWM2OD1zMT6yOlE6KM7:TR?=NIP3OWRUSU6JRWK=
SF295MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrxe2tKSzVyPUGxMlMyODRizszNMW\TRW5ITVJ?
YH-13MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTGTWM2OD1zMT6zNlY4KM7:TR?=M4TafXNCVkeHUh?=
SW837M1nMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{KwcGlEPTB;MUGuN|UxPiEQvF2=NF7zZZdUSU6JRWK=
KYSE-450NHvMWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\YTWM2OD1zMT60NFU4KM7:TR?=NWDPN|lwW0GQR1XS
KYSE-180M1zFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7OZYNKSzVyPUGxMlQ5OiEQvF2=M{m4NHNCVkeHUh?=
S-117NXTSXWVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\afolMUUN3ME2xNU41QDl4IN88US=>NXLlRoxqW0GQR1XS
KOSC-2Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\kRnNKSzVyPUGxMlYzOjJizszNMoG3V2FPT0WU
KYSE-270NFy3W4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEW2WY9KSzVyPUGxMlg4PDVizszNM4C2c3NCVkeHUh?=
D-336MGMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTFzLkmwO|Uh|ryPM1i0c3NCVkeHUh?=
KALS-1Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1S2[mlEPTB;MUKuNFAyPiEQvF2=NYixb3NmW0GQR1XS
LB373-MEL-DMorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPqRlVnUUN3ME2xNk4xPTN|IN88US=>NFjEeWpUSU6JRWK=
HLENHzubFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHPTWM2OD1zMj6wOVg2KM7:TR?=M{H2cnNCVkeHUh?=
SJSA-1M3KzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1K2TWlEPTB;MUKuNFc{PSEQvF2=MX\TRW5ITVJ?
SW1990NFX3PVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fDWmlEPTB;MUKuNFkyOSEQvF2=NEnHe21USU6JRWK=
NOS-1MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTF{LkGzOVIh|ryPNWfiNmhmW0GQR1XS
GI-ME-NMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmK1TWM2OD1zMj6yNVY{KM7:TR?=M3L1TXNCVkeHUh?=
NCI-H1703MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnwTWM2OD1zMj6yOlE3KM7:TR?=MYTTRW5ITVJ?
ES7MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXniblBPUUN3ME2xNk4zPzJ2IN88US=>M{m1cXNCVkeHUh?=
KYSE-510MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzXcZdFUUN3ME2xNk42ODd7IN88US=>MVTTRW5ITVJ?
BHYMmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLoXoFKSzVyPUGyMlU{ODdizszNNYLsdXI6W0GQR1XS
TCCSUPMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;RTWM2OD1zMj61O|U4KM7:TR?=NH;B[lZUSU6JRWK=
HSC-2MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoK0TWM2OD1zMj61PVk3KM7:TR?=NGrtW4lUSU6JRWK=
BENMoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTF{Lk[xOFMh|ryPMU\TRW5ITVJ?
769-PMnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPqTWM2OD1zMj63PVI1KM7:TR?=MWDTRW5ITVJ?
HTNHraXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moe3TWM2OD1zMj64N|Q3KM7:TR?=NGXoUXdUSU6JRWK=
LXF-289NECwSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTF{Lkm1N|Eh|ryPMXPTRW5ITVJ?
OVCAR-3MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrJXnV1UUN3ME2xNk46PTZ5IN88US=>NVfq[3d3W0GQR1XS
ATN-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mli4TWM2OD1zMz6wNVg1KM7:TR?=NHzR[IJUSU6JRWK=
8-MG-BANYXJdGpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnvTWM2OD1zMz6wOFU2KM7:TR?=NYS1cpBzW0GQR1XS
SW13NVnMdJlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7tTWM2OD1zMz6xNVY2KM7:TR?=NH3Bbo9USU6JRWK=
NCI-H1092MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTF|LkG2NkDPxE1?NXXkbmNEW0GQR1XS
OAW-42NGq0XHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vNcWlEPTB;MUOuNVk{PyEQvF2=MWrTRW5ITVJ?
NCI-H2452M4THPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XEUGlEPTB;MUOuNlE4PSEQvF2=MofFV2FPT0WU
CAPAN-1MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLJTWM2OD1zMz61OVE1KM7:TR?=MX;TRW5ITVJ?
NCI-H2009MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTUTGVbUUN3ME2xN{42QTF7IN88US=>NFXIN|RUSU6JRWK=
SF268M1:0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjWTWM2OD1zMz62N|I3KM7:TR?=M4H3UXNCVkeHUh?=
GCIYNVT5RlRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1exS2lEPTB;MUOuOlkzPyEQvF2=M2HaU3NCVkeHUh?=
OS-RC-2MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFz2XI1KSzVyPUGzMlk2ODFizszNMnT0V2FPT0WU
GCTNXPHU4w3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVT1e296UUN3ME2xN{46Pjl5IN88US=>NVT4N|NpW0GQR1XS
NB17MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTF2LkC4OUDPxE1?MoiyV2FPT0WU
NCI-H2030NGnXUJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTF2LkG0OlUh|ryPM2faR3NCVkeHUh?=
HC-1MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXPTWM2OD1zND6yNFg4KM7:TR?=MWLTRW5ITVJ?
QIMR-WILMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PVWmlEPTB;MUSuN|QyOiEQvF2=NYrtcVRRW0GQR1XS
Capan-2M1nobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\VcWlEPTB;MUSuN|cyPCEQvF2=NHToO3NUSU6JRWK=
BALL-1Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGm0c3NKSzVyPUG0MlQ3PjVizszNMl\MV2FPT0WU
LS-1034NY[1N2twT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTF2Lk[xOVIh|ryPMojKV2FPT0WU
U-118-MGMlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHNTWM2OD1zND62N|Eh|ryPNHLsXmRUSU6JRWK=
NCI-H630NFzHeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTF2Lk[1Olgh|ryPNF\2bGlUSU6JRWK=
OVCAR-8NH\WRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2n3eWlEPTB;MUSuO|IxOSEQvF2=M3XYV3NCVkeHUh?=
NCI-H2347MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\PbpczUUN3ME2xOE45OjNizszNNWnwe2xbW0GQR1XS
BT-549Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3uxdGlEPTB;MUSuPFI5PCEQvF2=NX7YNpc2W0GQR1XS
LB831-BLCNX3uWmp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HEUGlEPTB;MUSuPFk{PCEQvF2=NUmwR4ZpW0GQR1XS
NCI-H661M3vHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTqe5dKSzVyPUG0Mlk2QSEQvF2=MlHJV2FPT0WU
MKN7M2n2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoD2TWM2OD1zNT6wNFk{KM7:TR?=NEn0NYNUSU6JRWK=
U-87-MGNHftTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvMRpMzUUN3ME2xOU4xQDl5IN88US=>NHLIN|dUSU6JRWK=
OVCAR-4M3Gy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\5TmlEPTB;MUWuNVQzPCEQvF2=NHW3OIFUSU6JRWK=
OE33NX24U2ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fBOGlEPTB;MUWuNVcyOSEQvF2=NX;HTFh{W0GQR1XS
EC-GI-10MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTF3LkKzOVch|ryPMnO0V2FPT0WU
AM-38NUjWPXF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPxOZNKSzVyPUG1MlI4OTdizszNMWTTRW5ITVJ?
NCI-H1563NYXpO4o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LSbGlEPTB;MUWuN|Q6KM7:TR?=MYfTRW5ITVJ?
SCC-4M4T4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTF3LkSxNFMh|ryPNIrPeHlUSU6JRWK=
Detroit562NXTkRYxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDNXHhKSzVyPUG1MlQ2PDdizszNMlvnV2FPT0WU
PC-14MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\qTWM2OD1zNT60PFY3KM7:TR?=M1:zfnNCVkeHUh?=
ES3Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fQcGlEPTB;MUWuOVM3KM7:TR?=MnjtV2FPT0WU
OCI-AML2M4Tmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmj5TWM2OD1zNT63OlE1KM7:TR?=NWnFeJpnW0GQR1XS
LU-134-ANVjTWHRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Moi0TWM2OD1zNT65NFE5KM7:TR?=MnOwV2FPT0WU
SASM1SwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PwN2lEPTB;MUWuPVM4OyEQvF2=NV3nNo1iW0GQR1XS
TGBC11TKBM1L6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTvTWM2OD1zNT65OFE1KM7:TR?=MU\TRW5ITVJ?
HOP-62NX32RmhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFGx[nVKSzVyPUG1Mlk2QTdizszNM17y[3NCVkeHUh?=
G-401NVPtc4NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\STWM2OD1zNT65OlQ6KM7:TR?=NX7HZWpPW0GQR1XS
NCI-H28MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfqNVJ[UUN3ME2xOk4xQDV4IN88US=>MWTTRW5ITVJ?
A204NXrNTYVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPJTWM2OD1zNj6yNFA3KM7:TR?=NGnWOXFUSU6JRWK=
NCI-H1299MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTF4LkKyPVEh|ryPNVrPNpRPW0GQR1XS
VMRC-RCZNF;0RXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3mUndKSzVyPUG2MlI2QTJizszNMmC3V2FPT0WU
BxPC-3NV;mTZRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\NTWM2OD1zNj6yPFU3KM7:TR?=M1PGUnNCVkeHUh?=
NCI-H2228NWXvOYp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTF4LkWxOVgh|ryPMl3zV2FPT0WU
NCI-H23M3P1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLKTWM2OD1zNj62NFc5KM7:TR?=MmnHV2FPT0WU
NKM-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTF5LkCxPFkh|ryPNXnBb|NPW0GQR1XS
KYSE-70MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;mUmlEPTB;MUeuNlg6KM7:TR?=NFvDOHRUSU6JRWK=
BB49-HNCMny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2G2SmlEPTB;MUeuOVY5PiEQvF2=NYPQb2YzW0GQR1XS
SCC-15NHjGOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nB[mlEPTB;MUeuPFQ4OyEQvF2=M1;xe3NCVkeHUh?=
D-247MGNEDDS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PyfGlEPTB;MUeuPVI1PyEQvF2=NVW2TY44W0GQR1XS
BB30-HNCNFTuOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTF6LkCzNVgh|ryPMX;TRW5ITVJ?
CAL-85-1NYjU[IhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\3UlRMUUN3ME2xPE4yQDB7IN88US=>MlPzV2FPT0WU
HT-3MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjTeGdKSzVyPUG4MlM6PzdizszNM2r5XHNCVkeHUh?=
KYSE-410M3W5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTF6LkS1O|ch|ryPNIfNW4JUSU6JRWK=
SW982MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nuOGlEPTB;MUiuOVY1QSEQvF2=NGHYWIVUSU6JRWK=
SW962MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILlWJFKSzVyPUG4MlU4ODJizszNNED0OZNUSU6JRWK=
Ramos-2G6-4C10NImyblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrmdmRKSzVyPUG4MlU6OjdizszNMkj6V2FPT0WU
OC-314M4rpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPUTWM2OD1zOD63N|g1KM7:TR?=MnLSV2FPT0WU
LS-123NIG4W41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4[2XWlEPTB;MUiuO|kxOSEQvF2=M33tOXNCVkeHUh?=
D-502MGNUTze|RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NECzZYxKSzVyPUG4MlgyOzlizszNNYjzWWZqW0GQR1XS
RO82-W-1NWDxNmhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3Xk[WlEPTB;MUiuPFI5QCEQvF2=Mnq1V2FPT0WU
HuO9NXnrU5piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXj1WGhSUUN3ME2xPU4yOzd7IN88US=>MnLrV2FPT0WU
ETK-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDMfoVKSzVyPUG5MlE5OjdizszNM4[2b3NCVkeHUh?=
SNU-387NXXTV5hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13NWmlEPTB;MUmuNVg5QSEQvF2=NYT0NpBCW0GQR1XS
SW1573NUGzUmxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LGRmlEPTB;MUmuNVk3QSEQvF2=NGDONppUSU6JRWK=
NTERA-S-cl-D1NVTkbVloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGi5WmZKSzVyPUG5MlIxODdizszNM4rRZnNCVkeHUh?=
SF126M2ewbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjWfY9SUUN3ME2xPU4{PTB{IN88US=>MoD1V2FPT0WU
Calu-3NVP4bYNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTF7LkSyN|ch|ryPNHH6UWVUSU6JRWK=
NCI-H1048MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUH1em5JUUN3ME2yNE4{OjZ4IN88US=>NHrV[XNUSU6JRWK=
NCI-H226M163SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH24OnRKSzVyPUKwMlQ{QTlizszNMojmV2FPT0WU
FTC-133MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLGdno{UUN3ME2yNE41PzB|IN88US=>MV7TRW5ITVJ?
SF539M1LyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHL6[4ZKSzVyPUKwMlUyPzJizszNNXzYU5g{W0GQR1XS
TE-6M1e4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjBO3R3UUN3ME2yNE45ODZ5IN88US=>M4XESHNCVkeHUh?=
UMC-11MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVH3eXo1UUN3ME2yNE46OTZ2IN88US=>M4PVUHNCVkeHUh?=
BeckerM2TRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorMTWM2OD1{MT6xNVE5KM7:TR?=NIfhXmtUSU6JRWK=
KP-4M17zTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33UZ2lEPTB;MkGuNVE6PiEQvF2=M1jrdXNCVkeHUh?=
ChaGo-K-1M1Ph[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXH4cFc5UUN3ME2yNU4{PjJ5IN88US=>M17rWXNCVkeHUh?=
CFPAC-1MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEmz[GxKSzVyPUKxMlM5PThizszNMlzWV2FPT0WU
A498M1Hy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLMTWM2OD1{MT61N|EzKM7:TR?=MVXTRW5ITVJ?
NCI-H1755M3X5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrnW41KSzVyPUKxMlY4PDFizszNNXnJNVdwW0GQR1XS
TI-73MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\STWM2OD1{Mj6zNlgh|ryPNX\qZWVEW0GQR1XS
NCI-H441M3PZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfxR5ZKSzVyPUKyMlU3QDlizszNMlK0V2FPT0WU
CaR-1NIH6OlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLIOXZyUUN3ME2yN{4xOjF|IN88US=>M2faWXNCVkeHUh?=
HCC1806NFnqOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vpeWlEPTB;MkOuNFU5OyEQvF2=M1;lU3NCVkeHUh?=
SNU-449Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XIXWlEPTB;MkOuN|I6KM7:TR?=MX3TRW5ITVJ?
EKVXMnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjkeVNKSzVyPUKzMlM6ODlizszNNW\aV3lpW0GQR1XS
DMS-114M2fsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\EZ2lEPTB;MkOuOVc3PSEQvF2=MVXTRW5ITVJ?
A704NITHUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7YTmExUUN3ME2yN{43OTB|IN88US=>NULa[XZLW0GQR1XS
LC-2-adMl7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPIelBKSzVyPUKzMlYyPDdizszNNV\TOXZYW0GQR1XS
VM-CUB-1NVr6U4JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTJ|LkezOFEh|ryPMlr4V2FPT0WU
PC-3MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LrRWlEPTB;MkSuNFUzPiEQvF2=MXXTRW5ITVJ?
HELNFLKXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\WSGlEPTB;MkSuNFg3PSEQvF2=Ml\XV2FPT0WU
ABC-1NXfke2JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLZdnhKSzVyPUK0MlI4OjlizszNNVPtc|B6W0GQR1XS
COLO-680NNFfhNndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml[2TWM2OD1{ND60O|Y1KM7:TR?=M33OPHNCVkeHUh?=
MZ1-PCNI\0VFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTJ2Lk[4O{DPxE1?MorrV2FPT0WU
NCI-H69MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rTeWlEPTB;MkSuO|M2PCEQvF2=MkfVV2FPT0WU
TE-1NHqyfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn:4TWM2OD1{NT6wOFk6KM7:TR?=NI[yWXNUSU6JRWK=
EW-3Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYL5b2ptUUN3ME2yOU4yOTNizszNNVy0fGlbW0GQR1XS
PANC-08-13MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDETWM2OD1{NT64NVA{KM7:TR?=MX\TRW5ITVJ?
NMC-G1NWO2PHZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljMTWM2OD1{Nj6wNFg5KM7:TR?=NH;XU4lUSU6JRWK=
BT-20NEPBWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjYcItFUUN3ME2yOk41PTR|IN88US=>NXfK[5V7W0GQR1XS
TGBC24TKBM4XBNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoO0TWM2OD1{Nj63N|MyKM7:TR?=NIPjWGJUSU6JRWK=
TE-11M3jsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDMTWM2OD1{Nj65PFk2KM7:TR?=Ml7tV2FPT0WU
ESS-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;n[5RIUUN3ME2yO{4{OjF4IN88US=>MoOyV2FPT0WU
JVM-3MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\QTWM2OD1{Nz62OFc2KM7:TR?=NEHndmhUSU6JRWK=
C3AMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGH0bI9KSzVyPUK3Mlg1QTZizszNNX;L[5J6W0GQR1XS
MDA-MB-157MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTJ5Lki3OVMh|ryPMkm4V2FPT0WU
KLEMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HaVGlEPTB;MkiuNVA2QCEQvF2=MmHoV2FPT0WU
ES1MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPtTWM2OD1{OD6xPFM5KM7:TR?=MYHTRW5ITVJ?
CAL-120NWr2NZE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTJ6LkO5PVkh|ryPMXTTRW5ITVJ?
NCI-N87NVHZN3VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTJ6LkWxNFUh|ryPM3LoenNCVkeHUh?=
RPMI-8226M3[5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFm1VIRKSzVyPUK5MlE5PDNizszNMnjGV2FPT0WU
COR-L88MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnMeWtOUUN3ME2yPU4zPDF7IN88US=>Ml7MV2FPT0WU
UACC-893MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;Wd2UyUUN3ME2yPU4{OTN5IN88US=>M2ni[XNCVkeHUh?=
C8166NGPpXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTJ7Lkm5PVYh|ryPMV\TRW5ITVJ?
J82NY\lR|dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLrXppsUUN3ME2zNE45OTR5IN88US=>MVzTRW5ITVJ?
PFSK-1M1jCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoX3TWM2OD1|MT6wOlU6KM7:TR?=M1HKWnNCVkeHUh?=
COLO-684NWPZ[nFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mly1TWM2OD1|MT60N|c1KM7:TR?=M3fyR3NCVkeHUh?=
CAL-72M2TRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rGU2lEPTB;M{GuOVczQSEQvF2=MYfTRW5ITVJ?
SNB75NYjOTJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorETWM2OD1|MT64PVch|ryPMlywV2FPT0WU
MDA-MB-415Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTNzLkm3OlIh|ryPMVXTRW5ITVJ?
SiHaNHjKZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk[3TWM2OD1|Mj60O|EyKM7:TR?=NETldVVUSU6JRWK=
NCI-H1648NGjxOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPhTWM2OD1|Mj65N|Q2KM7:TR?=Mo\zV2FPT0WU
EFO-21MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTHS3pKSzVyPUOzMlAxPSEQvF2=Mn6xV2FPT0WU
HCC38M3PWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nHUmlEPTB;M{OuN|g1OSEQvF2=NYnvOGNPW0GQR1XS
IA-LMM3LGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NICyVWlKSzVyPUOzMlc5QDlizszNNXHZcXBsW0GQR1XS
CTV-1NF7j[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;OTWM2OD1|Mz65O|g3KM7:TR?=MWnTRW5ITVJ?
NCI-H446MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLaTWM2OD1|ND6yOlg6KM7:TR?=M1XpWnNCVkeHUh?=
IST-SL1NGn1R29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTN2Lke0NFgh|ryPM4P0OnNCVkeHUh?=
EW-22NF\GcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTPR2RKSzVyPUO0Mlc4PTlizszNMljoV2FPT0WU
JEG-3NFvldlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknJTWM2OD1|Nj6xO|Y3KM7:TR?=MVPTRW5ITVJ?
LU-65NGnyVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTN4LkK5PFUh|ryPNEj4UYVUSU6JRWK=
NCI-H596Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF62[5BKSzVyPUO2Mlk2QTFizszNNYrFeZNKW0GQR1XS
KNS-81-FDMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2faSGlEPTB;M{euNVQ2KM7:TR?=MXfTRW5ITVJ?
NCI-H1793NUXGSmd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfnWXNKSzVyPUO3MlcxQDZizszNMl2xV2FPT0WU
NCI-H460NHzKSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HiNGlEPTB;M{iuNFg4OyEQvF2=MkfjV2FPT0WU
MPP-89M2rhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\le2lEPTB;M{muOVg5PiEQvF2=MlX5V2FPT0WU
D-542MGMmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfvVpA{UUN3ME2zPU45PDN4IN88US=>NIrzS2VUSU6JRWK=
JARNGjiXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\nc4VKSzVyPUSwMlQ4ODVizszNMXTTRW5ITVJ?
NCI-H209M1niWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvsTWM2OD12MD62O|ch|ryPMoXhV2FPT0WU
G-402M2H6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFP1SZNKSzVyPUSxMlM6QTNizszNNV;BPHd2W0GQR1XS
IST-MES1NIm2OJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXQfnZKSzVyPUSyMlE6OzVizszNM4PP[nNCVkeHUh?=
DaoyMmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TkWGlEPTB;NEKuOVQ4OSEQvF2=NFH1RphUSU6JRWK=
EW-11NEPaVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\YTpVYUUN3ME20N{4yOjFzIN88US=>M2\me3NCVkeHUh?=
Saos-2MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTR|LkG1N|ch|ryPMWTTRW5ITVJ?
no-10NGHPOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnoWo5YUUN3ME20N{4yPzB{IN88US=>M1TWfXNCVkeHUh?=
HCC1395NXzKR4w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrvR3ZKSzVyPUSzMlQ3PDRizszNMXHTRW5ITVJ?
HCE-4MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1y5bGlEPTB;NEOuO|Y3PCEQvF2=NXrNfVBFW0GQR1XS
EW-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mkn4TWM2OD12Mz64NFQ6KM7:TR?=MUjTRW5ITVJ?
OCUB-MMoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLTTWM2OD12ND6zOlM5KM7:TR?=NUHIWpRiW0GQR1XS
IGR-1Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFT1RXRKSzVyPUS0MlQyOTVizszNM3e1XXNCVkeHUh?=
NCI-H1838MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFS0TYxKSzVyPUS0MlQ{PDlizszNMmSzV2FPT0WU
NCI-H2405M3PDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrCTWM2OD12ND61N|Qh|ryPNH\lb4dUSU6JRWK=
GB-1NXjNTXltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HuV2lEPTB;NESuO|Q3OyEQvF2=MYPTRW5ITVJ?
MG-63NIPvVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTR4LkC2PVYh|ryPM3zjTXNCVkeHUh?=
KP-N-YNM2nvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTR4LkS2O|kh|ryPM3HrT3NCVkeHUh?=
no-11MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3N[GJKSzVyPUS3MlAzPDRizszNNHPhbZdUSU6JRWK=
SW948NWC1XGZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPZSVNKSzVyPUS3MlM{PzdizszNM1SxXnNCVkeHUh?=
CAMA-1NVfPbmlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDBTWM2OD12Nz6zOFM5KM7:TR?=NXHBfmxVW0GQR1XS
HCC1187MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoOzTWM2OD12Nz61NUDPxE1?NHvmUXRUSU6JRWK=
D-392MGMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHhVHdKSzVyPUS3MlY2OTZizszNMk\BV2FPT0WU
647-VNXTMWIdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm[1TWM2OD12OT6zOFE1KM7:TR?=MX;TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]
Features First MEK inhibitor to begin clinical development.

Protocol(Only for Reference)

Kinase Assay:

[2]

MEK1 Assay MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.

Cell Assay:

[1]

Cell lines Colon 26 carcinoma cells
Concentrations 0.1-10 μM
Incubation Time 24 hours
Method

Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.

Animal Study:

[3]

Animal Models PTC cells in athymic mice
Formulation Cremophor EL–95% ethanol (50:50) and dilutes with water
Dosages 150 mg/kg
Administration Orally twice daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Sebolt-Leopold JS, et al. Nat Med, 1999, 5(7), 810-816.

[2] Davies SP, et al. Biochem J, 2000, 135(1), 95-105.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Insti  ...more University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Chemical Information

Download PD184352 (CI-1040) SDF
Molecular Weight (MW) 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related MEK Products

  • Cobimetinib (GDC-0973, RG7420)

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM. Phase 3.

  • BI-847325

    BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.

  • GDC-0623

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.

  • Trametinib (GSK1120212)

    Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

    Features:More potent than PD0325901 or AZD6244.

  • PD0325901

    PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

  • Selumetinib (AZD6244)

    Selumetinib (AZD6244) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM in cell-free assays, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

    Features:First MEK inhibitor being tested in Phase II clinical trials.

  • U0126-EtOH

    U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

    Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.

  • PD98059

    PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

    Features:Does not inhibit c-Raf phosphorylated MEK1.

  • Binimetinib (MEK162, ARRY-162, ARRY-438162)

    Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.

  • Refametinib (RDEA119, Bay 86-9766)

    Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Recently Viewed Items

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us